COLORADO SPRINGS, Colo.,
Dec. 5, 2014 /PRNewswire/ -- Cannabis
Science, Inc. (OTCQB: CBIS), a U.S. company specializing in global
cannabis formulation-based drug development and consulting, is in
the final stages of its preparations to launch new products
throughout the California market,
including extracts, oils, tinctures, tablets, and creams.
"All that's left now is to finish work on the packaging and the
labeling, and that should only take a matter of days," said Mr.
Raymond C. Dabney, Director,
President & CEO and Co-Founder of Cannabis Science
Inc. "The products and the formulation are there. We're ready
to launch in California and we're
excited, as I'm sure many self-medicating patients are."
The California launch was made
possible by a renegotiation of the Cannabis Science agreement with
Apothecary Genetics Investments LLC. The new agreement enabled
Cannabis Science to purchase and license two northern California production farms with a combined
total of 51 acres. The purchase included all related equipment for
cannabis cultivation and production for the state's substantial
medical cannabis market and gives Apothecary Genetics the right to
sell Cannabis Science formulations throughout the State of California.
"Apothecary Genetics is state licensed and regulated, and now
with our new licensing agreement we can proceed with the
commercialization of our medical cannabis formulations throughout
the State," said Mr. Dabney.
Mr. Dabney said the company will provide more information about
the release of its products and where they will be available in the
coming days.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique
understanding of metabolic processes to provide novel treatment
approaches to a number of illnesses for which current treatments
and understanding remain unsatisfactory. Cannabinoids have an
extensive history dating back thousands of years, and currently,
there are a growing number of peer-reviewed scientific publications
that document the underlying biochemical pathways that cannabinoids
modulate. The Company works with leading experts in drug
development, medicinal characterization, and clinical research to
develop, produce, and commercialize novel therapeutic approaches
for the treatment for illnesses caused by infections as well as for
age-related illness. Our initial focus is on skin cancers and
neurological conditions.
Forward-Looking Statements
This Press Release
includes forward-looking statements within the meaning of Section
27A of the Securities Act of 1933 and Section 21E of the Securities
Act of 1934. A statement containing words such as "anticipate,"
"seek," intend," "believe," "estimate," "expect," "project,"
"plan," or similar phrases may be deemed "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. Some or all of the events or results
anticipated by these forward-looking statements may not occur.
Factors that could cause or contribute to such differences include
the future U.S. and global economies, the impact of competition,
and the Company's reliance on existing regulations regarding the
use and development of cannabis-based drugs. Cannabis Science,
Inc., does not undertake any duty nor does it intend to update the
results of these forward-looking statements.
Cannabis Science, Inc.
Raymond C. Dabney, Director,
President & CEO, Co-Founder
raymond@cannabisscience.com
Tel: 1.310.650.3788
Chad S. Johnson, Esq., Director,
COO, & General Counsel
www.cannabisscience.com
info@cannabisscience.com
1.888.777.0658
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/cannabis-science-cbis-readies-to-launch-new-products-in-california-with-apothocary-genetics-300005429.html
SOURCE Cannabis Science, Inc.